New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea

Gonorrhea Clinical Trial

— NABOGO  

Official title:

New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03294395
• Other study ID #: NABOGO
• Status: Completed
• Phase: Phase 3
• Start date: September 18, 2017
• Est. completion date: June 5, 2020

Study information

• Verified date: July 2021
• Source: Public Health Service of Amsterdam
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the efficacy of three experimental antibiotics in the treatment of uncomplicated anogenital gonorrhoea. Participants will be randomized to one of four study arms and will receive either one of the three experimental antibiotics (ertapenem, fosfomycin and gentamicin) or the current standard antibiotic (ceftriaxone). Both the study team and the participant are blinded to the administered treatment. This enables the investigators to compare the eradication capacity and safety of the experimental antibiotics with the standard treatment.

*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.

Description:

Antimicrobial resistance (AMR) to extended spectrum cephalosporins (ESC) among Neisseria gonorrhoeae (Ng) is a major public health concern. With no alternative antimicrobial treatment options for gonorrhoea and only a few new drugs in the development pipeline, it is important to test existing antibiotics for their efficacy in gonorrhoea treatment. This project aims to identify new treatment modalities for uncomplicated gonorrhoea using the registered drugs ertapenem, fosfomycin and gentamicin. This trial is a double blind randomized clinical non-inferiority trial with four treatment arms. 108 participants are randomly assigned to each study arm . Participants will receive either ceftriaxone 500mg intramuscularly (IM) or ertapenem 1000mg IM or gentamicin 5mg/kg IM with a maximum of 400mg (in two doses) supplemented with an oral placebo, or receive fosfomycin 6g oral suspension supplemented with an intramuscular placebo. The bacterial eradication capacity of the study antimicrobials at the included infection site is measured 7-14 days after treatment, using an RNA-based Nucleic Acid Amplification Test (NAAT).

*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 346
• Est. completion date: June 5, 2020
• Est. primary completion date: June 5, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria main study

• 18 years or older

• Anorectal, cervical/vaginal or urethral Ng infection, diagnosed by the following:

• Ng-positive Gram-stained smear (intracellular Gram-negative diplococci and leukocytes) and/or

• Positive for Ng by nucleic acid amplification test (NAAT) (Aptima Combo 2) and/or

• Positive for Ng by culture

• Provide samples from the included infection site for NAAT and direct culture immediately before treatment

• Willing to abstain from anal, vaginal and oral sex until the test of cure (TOC)-visit, or use condoms during sex

• Willing and able to return for a TOC-visit 7-14 days after treatment

• Provide informed consent

• Accept intramuscular injections

Exclusion criteria main study

Pre-randomisation:

• Suspicion of a complicated Ng infection based on signs and/or symptoms indicating pelvic inflammatory disease (PID), epididymitis, prostatitis or gonococcal arthritis*

• Another (sexually transmitted) infection or a suspicion of another infection for which systemic antimicrobial therapy is indicated

• Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)

• Not able to read/understand Dutch or English

• HIV infection if:

• Newly diagnosed HIV infection (upon the inclusion visit) and/or

• CD4+ cell-count <200 cells/µL (as reported by the patient)

• Known allergy or adverse reactions to ceftriaxone, ertapenemor gentamicin

• Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR = 50 ml/min)

• Known liver cirrhosis (based on history)

• Known congestive heart failure (based on history)

• Known myasthenia gravis

• Known hearing loss or balance disorder, confirmed by an ear-nose-throat (ENT)-doctor or for which an ENT doctor has been consulted and a diagnostic process is still in progress (based on history)

• Concurrent use of any of the following medication:

• systemic antibacterial antimicrobials other than nitrofurantoin or metronidazole

• systemic immunosuppressive drugs

• systemic valproic acid

• Use of any antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)

• Previous enrollment in the study

• Concurrent participation in other non-observational medical research*

• Unlikely to adhere to the study protocol

Post-randomisation:

Exclusion of participants from the modified intention to treat analysis (mITT):

• Negative result of Ng NAAT of sample collected on T0 (the day of treatment). This could be the case in the following situations:

1. Negative NAAT in spite of positive gram stain.

2. Positive NAAT on pre-study visit but spontaneous clearance of the infection in the time period between first test and return visit for treatment (=study inclusion visit). A novel sample for NAAT will be collected on the study inclusion visit just before administration of treatment; if these results are Ng-negative a participant will be excluded of mITT.

• Loss to follow-up, i.e. no study visit TOC 7-14 days after treatment administration.

Exclusion from per protocol analysis (PP):

• Exclusion of mITT

• Use of non-study related antibiotics after inclusion and prior to TOC visit

• Condomless sexual contact with the primary anatomical gonorrhea site involved after inclusion and prior to TOC visit

• Other protocol violations

Inclusion criteria PK substudy (healthy volunteers):

• 18 years or older

• Provide informed consent

Exclusion criteria PK substudy (healthy volunteers)

Pre-randomisation:

• Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)

• Not able to read/understand Dutch or English

• Known allergy or adverse reactions to ceftriaxone, ertapenem, or fosfomycin.

• Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR = 50 ml/min)

• Known liver cirrhosis (based on history)

• Concurrent use of any of the following medication:

• systemic valproic acid

• systemic metoclopramide

• Use of any systemic antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)

• Concurrent participation in other non-observational medical research (apart from NABOGO RCT)

• Unlikely to adhere to the study

Related Conditions & MeSH terms

• Gonorrhea

Intervention

Drug:
• Ertapenem 1000 MG
single dose 1000mg intramuscular injection
• Fosfomycin Oral Suspension
single dose 6g oral suspension
• Gentamicin Sulfate, Injectable
single dose 5mg/kg (maximum 400mg) intramuscular injection
• Ceftriaxone
single dose 500mg intramuscular injection

Locations

Country	Name	City	State
Netherlands	Public Health Service	Amsterdam	Noord Holland

Sponsors (2)

Lead Sponsor	Collaborator
Public Health Service of Amsterdam	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants with treatment success in each study arm for the included anatomic infection	Proportion of participants with treatment success in each study arm using a molecular test (Nucleic acid amplification test, NAAT). Treatment succes is defined as a negative test of cure (NAAT) 7-14 days after treatment.	7-14 days after treatment
Secondary	Proportion of participants with treatment success in each study arm at all anatomical infection sites	Proportion of participants with treatment success in each study arm using a molecular test (Nucleic acid amplification test, NAAT). Treatment succes is defined as a negative test of cure (NAAT) 7-28 days after treatment.	7-28 days after treatment
Secondary	Incidence of treatment-emergent adverse events	The incidence, type and severity of treatment-related adverse events as assessed by CTCAE v4.0 will be measured.	until 30 days after treatment
Secondary	Antimicrobial susceptibility of Ng-strains to study antibiotics	The in vitro antimicrobial susceptibility (in MIC) of the experimental and reference treatment will be measured in all Ng strains collected at all infected anatomical sites of each participant at inclusion and in case of a positive test of cure.	Day 0 (before treatment) - 28 (after treatment)
Secondary	Blood plasma concentration of ceftriaxone, ertapenem and gentamicin in a subset of 60 NABOGO participants	The blood plasma concentration will be measured 1 times within the first 24 hours after treatment administration. With these measurements the investigators will estimate the population pharmacokinetics of ceftriaxone, ertapenem and gentamicin.	within 24 hours after treatment administration
Secondary	Duration of symptoms after treatment	All participants are asked to report their symptoms daily in a diary, this will be evaluated at the follow-up visit (7-14 days after treatment) and at the online evaluation questionnaire (30 days after treatment). The mean duration of all symptoms after treatment will be measured for all study antibiotics.	1-30 days after treatment
Secondary	Clinical and demographic predictors for treatment failure	The investigators will measure if demographic (e.g. gender, HIV status) and clinical factors (e.g. anatomical location, duration of symptoms before treatment) are associated with treatment failure (treatment failure is defined as any case in which the participant received escape medication).	until 7-14 days after treatment
Secondary	Blood plasma concentration of ceftriaxone, ertapenem and fosfomycin in 60 healthy volunteers	Healthy volunteers will be randomly assigned to one of the three antibiotics. After administration of the antibiotic, the blood plasma concentration will be measured 4 times within the first 24 hours. With these measurements the investigators will estimate the population pharmacokinetics of ceftriaxone, ertapenem and fosfomycin.	24 hours